Results 181 to 190 of about 18,957 (200)

Rivastigmine

Reactions Weekly, 2019
openaire   +2 more sources

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study

Lancet Neurology, The, 2007
Bengt Winblad, Sibel Tekin, Alistair Burns   +2 more
exaly  

Double Optimization of Rivastigmine-Loaded Nanostructured Lipid Carriers (NLC) for Nose-to-Brain Delivery Using the Quality by Design (QbD) Approach: Formulation Variables and Instrumental Parameters

Pharmaceutics, 2020
Sara Cunha, Cláudia Pina Costa, Joana A Loureiro   +2 more
exaly  

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease

Movement Disorders, 2006
David Burn, Ian G Mckeith, Dag Aarsland
exaly  

Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial

Lancet Neurology, The, 2016
Emily J Henderson Frcp, Stephen R Lord, Matthew A Brodie   +2 more
exaly  

Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer’s disease

Biomaterials, 2010
Guillaume Bastiat, Gregor Fuhrmann, Jean-Christophe Leroux   +2 more
exaly  

Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease

European Journal of Medicinal Chemistry, 2017
Maria Digiacomo, Qiong Gu, Yifan Han
exaly  

Rivastigmine

Reactions Weekly, 2009
openaire   +1 more source

Optimization of brain targeted chitosan nanoparticles of Rivastigmine for improved efficacy and safety

International Journal of Biological Macromolecules, 2013
Kalpana Nagpal, D N Mishra
exaly  

Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting

European Journal of Pharmaceutical Sciences, 2012
Mohammad Fazil, Shadab, Shadabul Haque
exaly